Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT02416830 |
| Other study ID # |
embocohort |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
March 31, 2015 |
| Last updated |
April 14, 2015 |
| Start date |
April 2014 |
| Est. completion date |
October 2019 |
Study information
| Verified date |
April 2015 |
| Source |
EmboCoH |
| Contact |
Jafar Golzarian, MD |
| Phone |
612-626-5388 |
| Email |
jafar[@]umn.edu |
| Is FDA regulated |
No |
| Health authority |
Japan: Institutional Review Board |
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The purpose of this cohort post market registry is to collect data and create a global
database on use of embolization devices and embolization procedures outcome. The data
collected in the cohort will serve a scientific purpose to acquire better insight in
embolization procedures. This will be achieved by publications in Scientific Journals and by
presentations at scientific meetings. Additionally it will support the industry on creating
a better overview of the products used to maintain and enhance the clinical efficacy of the
used devices. The cohort post market registry represents a novel approach in a way of
allowing Clinicians to generate reports based on an evolving controlled and well organized
database
Description:
INTRODUCTION
Purpose:
The purpose of this cohort post market registry is to collect data and create a global
database on use of embolization devices and embolization procedures outcome. The data
collected in the cohort will serve a scientific purpose to acquire better insight in
embolization procedures. This will be achieved by publications in Scientific Journals and by
presentations at scientific meetings. Additionally it will support the industry on creating
a better overview of the products used to maintain and enhance the clinical efficacy of the
used devices. The cohort post market registry represents a novel approach in a way of
allowing Clinicians to generate reports based on an evolving controlled and well organized
database.
Hypothesis:
Transcatheter Embolization is a recognized primary treatment of various diseases and a
viable alternative to existing treatment options. Further that the Registry will foster
generation of Consensus Treatment Documents for the benefit of the Clinicians involved in
Transcatheter Embolization. Further that the Registry will increase the level of
Transcatheter Embolization as a function of Clinicians getting access to data generated in
the Registry.
Embolization indications:
The current set-up of the registry focuses on the embolization treatment of visceral
arterial aneurysms. In future additional indications for embolization will be added to the
scope of the study.
Significance to the scientific field:
A few key opinion leaders in the field of Interventional Radiology (IR), , have identified
the need for providing improved clinical evidence on embolization procedures.
There are several factors potentially explain today's limited evidence including:
- rapidly evolving technology,
- absence of consensus on clinical indications/interventional strategy,
- small sample size in term of number of cases/centre/year;
- lack of support from the university/public funding resources as well as the industry,
- low level of required qualification/certification for devices from companies before and
during the commercialization process of embolization devices/technologies
All these elements are concurrent toward a need to facilitate independent, high quality,
evaluation of clinical outcomes of embolization in a widespread spectrum of applications
resulting in publications with a high scientific value and of significance to the healthcare
systems.
Registry overview:
A prospective, multi-center, non-randomized cohort registry collecting data of technical and
clinical outcome of embolization procedures from participating centers on a standard of care
basis.
Duration of the registry:
The estimated duration of the registry is approximately 5 years from the time of first
subject enrollment. Subjects will be followed according the standard of care procedures of
the participating centers.
Number of sites and subjects:
No limitation has been set on the number of participating sites and subjects. The
participating sites will be granted participation approval by one or both co-principal
investigators.
Participating investigators:
For physicians and clinical centres to be able to participate in the study they have to be
approved by the founders, Marc Sapoval, M.D PhD (Doctor of Philosophy) and Jafar Golzarian,
MD and John Kaufman M.D. The founders can name a group of expert as lead principal
investigators (LPI) who can represent the founders in each registry.
Only centers and physicians that have the facilities and expertise required for the study
can participate in this study.
All participating centers must sign the EmboCoH Charter in order to participate.
EmboCoH is a non for profit organization founded by Marc Sapoval and Jafar Golzarian.
Data Management and Quality Assurance:
The selected platform is e-capture.net. This platform is a property of e-novex. e-novex
offers secure and innovative solutions to enhance and conduct e-clinical trials in
compliance with the different regulations. e-novex is ISO9001 and ISO27001 certified, ISO is
the International Organization for Standardization. The platform is Code of Federal
Regulations Title 21, part 11 (21 CFR, part 11) compliant.
Publications and Sharing Data:
Publications will be reviewed by the Steering Committee prior to submission for publication.
EmboCoH will encourage and drive publications in Journals and at Scientific Meetings.
EmboCoH will lead the formation of Consensus Documents based on Clinical Outcomes in the
database.
Contact information:
Organizational lead:
EmboCoH 17010 40th Place N. Plymouth, MN 55446 (Minnesota) USA EmboCoH is a non for Profit
Organization.
Project management:
Gert Andersen gert@transmedicalalliance.com Mob: +45 23 600 650
REGISTRY METHODOLOGY
Registry design:
This is a prospective, multi-center, non-randomized registry. All consecutive subjects
eligible for embolization of visceral aneurysms may be included in the registry. Additional
indications for embolization may be added to the scope during the course of the registry.
Purpose of the registry:
The purpose of the registry is to provide a worldwide therapeutic embolization data base to
provide data and evidence in the field of IR with a focus on embolization and oncology. The
data is to be published and can be shared with selected medical and industry professionals.
Primary objective:
The primary objective is collection of initial embolization procedure results and defined as
target vessel or lesion occlusion and clinical success.
Secondary objective:
The secondary objective is to collect the organ specific procedural results and outcome.
General inclusion data:
Subjects must meet the following criteria in order to participate within the study:
- Eligible for embolization as defined within the scope of the study.
- Subject (or subject's legally authorized representative) is able and willing to sign
the data protection form if and when applicable.
Subject screening & selection:
No specific screening protocol is applicable for the cohort registry. Assessment of patient
eligibility is performed as per standard of care and is performed based on data available to
the investigator at the time of subject enrollment. Procedure data collection requirements
All available data on the initial embolization procedure and organ specific procedure will
be collected in the electronic Case Report Form (eCRF).
Follow-up visit data collection:
All subjects will be clinically followed-up as per standard of care of the participating
hospital to assess if clinical success was maintained, to evaluate the current health status
and whether re-intervention occurred. Imaging follow-up will be included when appropriate
and as per standard of care.
It is recommended to have the patients come in for a follow-up visit at one (1), six (6) and
12 months for visceral aneurysms.
Regulatory and Institutional approvals:
The platform is considered to be a non-interventional registry. No formal investigational
plan will be created, however available data will be centrally stored outside the hospital
and therefore must be compliant with the national or local regulations.
It is the responsibility of each involved center to verify the local requirements prior to
the participation. It is strongly recommended to use a written consent form, approved by the
relevant institutional review board or ethical committee that confirms the approval of the
patient to store anonymous data centrally.
The selected platform is compliant with the overall data protection regulation. Personal
access is granted after the approval of the Project Management.
Termination of participation:
All subjects have the right to terminate themselves from participation at any point during
the study.
